YBOC.F · Tenax Therapeutics, Inc

-

Please sign in to comment on YBOC.F

1 Comment

Admin

4 years ago

Tenax Therapeutics, Inc is currently in a long term uptrend where the price is trading 8.8% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Tenax Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 1.4% to $-3M since the same quarter in the previous year.

Finally, its free cash flow fell by 15.3% to $-2M since the same quarter in the previous year.

Based on the above factors, Tenax Therapeutics, Inc gets an overall score of 2/5.

Exchange	F
CurrencyCode	EUR
ISIN	None
Sector	Healthcare
Industry	Biotechnology

Market Cap	245K
PE Ratio	None
Target Price	4.75
Dividend Yield	0.0%
Beta	2.13

ABOUT

Tenax Therapeutics, Inc

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

YBOC.F · Tenax Therapeutics, Inc

-

Tenax Therapeutics, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Tenax Therapeutics, Inc using a moving average strategy